Tobacco Manufacturing (United States) — NAICS 312230

A Histometrics industry primer for public-market and private investors.

1. Overview

Tobacco manufacturing is the business of turning cured tobacco leaf into finished consumer products — cigarettes, cigars, chewing tobacco, snuff and pipe tobacco — plus the leaf-processing (stemming and redrying) step that feeds those factories.[1] It is one of the most unusual industries in the U.S. economy: a shrinking customer base, a product that is heavily taxed and litigated, and yet extraordinary profitability and cash generation. Roughly 125 U.S. establishments and about 11,400 workers produced close to $51 billion of shipments, because addiction gives makers durable pricing power and excise taxes discourage new entrants.[2][3] BLS estimates current-dollar sectoral output at $61.6 billion in 2025, reflecting the distinction between factory-gate receipts and gross output adjusted for inventories and transfers.[4]

Why an investor cares: this is a classic "cash cow" sector. Owners make money less by growing units — cigarette volumes fall high-single-digits every year — and more by raising prices faster than volumes decline, then returning the cash as dividends and buybacks.[5][6] The forward question is whether newer smoke-free products (nicotine pouches, heated tobacco, vapes) can grow fast enough to replace the combustible cigarette business as it fades.

Public vs. private ways in: unusually, almost the entire industry is already inside public companies — U.S.-listed Altria and Philip Morris International, plus British American Tobacco (owner of the U.S. #2, Reynolds American), Imperial Brands (owner of ITG Brands), and Japan Tobacco (owner of #4, Liggett).[7][8][9] Genuinely private plays are scarce and sit mostly in leaf supply, cigars, distribution and nicotine-product startups (Section 10).

2. What it is and how it's structured

NAICS (North American Industry Classification System) code 312230 covers establishments that (1) stem and redry tobacco and/or (2) manufacture cigarettes, cigars, chewing tobacco, snuff and prepared pipe tobacco.[1] Note that as of the 2017/2022 NAICS revisions, cigarettes and "other tobacco" were merged into this single code.

What it excludes — important for sizing the real nicotine economy:

• Tobacco farming (growing the leaf) is NAICS 111910, not manufacturing.[1]
• Leaf wholesalers/brokers are NAICS 424940 / 425120.[1]
• Electronic cigarettes and vape devices are NAICS 339999 (All Other Miscellaneous Manufacturing), and e-liquid is NAICS 325998 (chemical preparations) — neither is in 312230.[1]

That last exclusion matters: the fastest-growing part of nicotine consumption — disposable vapes and e-liquid — falls outside this industry code entirely, so "tobacco manufacturing" statistics increasingly miss where the market is heading.

A major boundary problem is oral nicotine. Tobacco-containing snuff and chew plainly belong inside the code; tobacco-leaf-free nicotine pouches are not clearly enumerated in the Census definition. Company "oral tobacco" segments can combine moist smokeless tobacco, tobacco-derived nicotine, and synthetic-nicotine pouches — these should not automatically be treated as NAICS 312230 revenue.

Ownership mix: the industry is dominated by a handful of large, brand-owning corporations rather than many small operators. Two of the four biggest U.S. cigarette businesses are foreign-controlled (British American Tobacco and Japan Tobacco), Imperial Brands owns ITG Brands (the third-largest U.S. cigarette manufacturer), one leaf processor operates globally, and the long tail is a modest number of cigar and smokeless-tobacco makers.[7][8][9]

3. How big it is

Ground-truth U.S. federal figures for NAICS 312230:

The standout is productivity: about $4.5 million of shipments per worker (dividing 2022 receipts by 2023 employment) — among the highest of any U.S. manufacturing industry, reflecting heavy automation, brand pricing and the tax-inflated value of each unit.[2][3]

Two caveats on what these numbers do and don't capture (this is a case where federal statistics are fairly complete on the manufacturers, but understate the broader nicotine economy):

• Factory receipts are well below consumer spending. The ~$51 billion is what manufacturers collect at the factory gate. At retail, most of a pack's price is excise tax and retail margin — federal plus average state cigarette tax alone runs about $2.97 per pack — so consumers spend far more than manufacturers receive.[11]
• The "American tobacco" footprint is bigger than the code. Marlboro's international volumes are made abroad by Philip Morris International, and the surging vape/pouch categories partly sit outside 312230, so this code understates the total nicotine business tied to U.S. firms.

Federal concentration data confirm this is a near-oligopoly: the top 4 firms account for 90.6% of receipts, the top 8 for 95.6%, and the top 20 for 98.7%.[3] (The Herfindahl-Hirschman Index, a standard concentration measure, is suppressed in the federal data for this industry.[3])

4. The investable universe

Unusually for a Histometrics primer, almost the whole industry is investable through public equities — but split between a U.S. pure-play, a global smoke-free growth story, and foreign parents of U.S. businesses.

Major private / foreign-owned owners (not directly investable on U.S. exchanges except via foreign parents):

• Reynolds American — the U.S. #2 cigarette maker; a private subsidiary of British American Tobacco (invest via BTI).[7]
• Liggett / Vector Group — the U.S. #4 (Montego, Eagle 20's, Pyramid); acquired by Japan Tobacco (JT Group, Tokyo-listed) in a ~$2.4 billion deal completed October 7, 2024, now delisted.[8]
• Swedish Match — maker of Zyn; owned by Philip Morris International.[6]
• Cigar and specialty makers (e.g., Scandinavian Tobacco Group, Copenhagen-listed; Swisher, private) round out the long tail.

Note for index and fund investors: many ESG-screened funds exclude tobacco entirely, so exposure often comes through broad consumer-staples funds (which hold MO and PM) rather than a dedicated U.S. tobacco ETF.

5. How the money works

The economics here are distinctive, so it's worth being specific about the levers owners actually pull.

Price over volume. The core model is not unit growth — U.S. cigarette pack sales fell about 9.2% in 2024 (to ~6.9 billion packs) and another ~8.2% in 2025; major manufacturers sold 173.5 billion cigarettes in 2022, down from 190.2 billion in 2021.[16][17] Instead, manufacturers raise net pack prices faster than volumes fall, so revenue and profit hold or grow. Altria's smokeable segment produced $17.4 billion of net revenue (after excise taxes) and $11.0 billion of operating income in 2025 even as sticks shipped kept declining — a 63% operating margin.[5] That pricing power comes from brand loyalty and the inelastic demand of an addictive product.

Very high margins, low capital needs. Cigarettes are cheap to make and highly automated; the value sits in the brand and the addiction, not the factory. That yields fat margins and strong free cash flow with little reinvestment — cash that flows to shareholders. Altria has raised its dividend for 55 straight years and yields around 7%, paying roughly $7 billion in dividends in 2025 on top of buybacks.[5][12] These margins should not be generalized to leaf processors, contract manufacturers, or cigars — the branded-cigarette economics are exceptional.

Taxes and settlement costs are a per-unit wedge. Federal excise tax is $1.01 per pack ($50.33 per 1,000 small cigarettes); pipe tobacco is taxed at $2.83 per pound, chewing tobacco at $0.50 per pound, snuff at $1.51 per pound, and roll-your-own tobacco at $24.78 per pound.[18] Average state tax adds about $1.96 per pack, and the 1998 Master Settlement Agreement adds a further per-pack cost (Section 7).[11][19] These act like variable costs that manufacturers largely pass through in price — one reason legal cigarettes are expensive and illicit alternatives find room.

Retail promotion is economically central. In 2022 major cigarette manufacturers spent $8.0 billion on advertising and promotion; $5.7 billion went to retailer price discounts and $1.1 billion to wholesaler discounts — together 85.9% of reported promotional spending.[17]

The new growth engine: smoke-free. Because combustibles are in structural decline, value is shifting to reduced-risk products:

• Nicotine pouches — the fastest-growing category. The U.S. pouch market was roughly $4 billion in 2024 and growing ~30%+ a year.[20] Zyn dominates with a ~74%+ share; PMI shipped 797.9 million nicotine-pouch cans in the Americas in 2025, growth driven predominantly by Zyn in the United States.[21][22] Altria's on! and BAT's Velo compete. Altria's tracked data put nicotine pouches at 53.3% of the U.S. oral category in 2025, up 10 percentage points from 2024.[5]
• Heated tobacco — PMI's IQOS heats rather than burns tobacco; a large international earner now re-entering the U.S.[6]
• Vapes — BAT's Vuse and Altria's NJOY, though the legal vape market is disrupted by illicit imports (Section 9).

These carry higher growth and, over time, competitive margins — the bet is that they replace combustible profit as it erodes.

Leaf processors are a different, thinner model. Universal Corporation makes money on volume handled times a modest processing/merchant margin, and carries heavy seasonal working capital to buy and finance crops — closer to an agricultural-commodity business than a branded-goods one.[14] Raw leaf is important operationally but small relative to finished-product value: USDA estimates the 2025 crop at 359 million pounds from 171,300 acres, with a preliminary value of $832 million at an average $2.32 per pound.[23][24]

6. What drives demand

• Long-run decline in smoking. The adult cigarette smoking rate hit a record-low 9.1% in 2025 (about 24 million adults), down from 9.9% in 2024 and 42.4% at the 1965 peak.[25] This secular decline is the single biggest force on the industry.
• Addiction and inelastic demand. Remaining smokers are relatively price-insensitive, which is what sustains price-led revenue despite falling volumes.[5]
• Substitution across nicotine formats. Consumers are migrating from cigarettes to pouches, vapes and heated tobacco — reshuffling where the profit sits rather than eliminating nicotine demand. Adult e-cigarette use was 6.7% in 2025.[20][25]
• Taxes and price. Higher excise taxes reduce volumes and push some buyers toward cheaper or illicit products; states with high taxes (e.g., New York at $5.35/pack) show more cross-border and illicit activity.[11]
• Demographics and income. Smoking skews toward lower-income and older cohorts; recessions can prompt "down-trading" to discount brands. Altria reported that the discount segment reached 31.8% of measured cigarette retail volume in 2025, up 2.2 percentage points, attributing the shift primarily to discretionary-income pressure.[5]
• Menthol concentration. Menthol cigarettes represented 36% of major-manufacturer volume in 2022, making any menthol restrictions a material demand risk.[17]
• Youth and new-user dynamics. Flavored disposable vapes have drawn younger users — a demand and regulatory flashpoint (Sections 7 and 9).[26]

7. Regulation

Tobacco is among the most heavily regulated U.S. consumer industries. Key pillars:

• FDA authority. Since the 2009 Tobacco Control Act, the FDA's Center for Tobacco Products (CTP) regulates tobacco products. New products need a Premarket Tobacco Product Application (PMTA) authorization to be legally sold; average review times have stretched toward ~700 days, a persistent industry complaint.[27]
• Modified-risk authorizations. In January 2025 the FDA authorized 20 Zyn pouch products to be marketed with a reduced-risk claim relative to cigarettes — a first-of-its-kind decision that validates the pouch category.[28]
• Menthol ban — proposed, not finalized. The FDA's proposed menthol-cigarette and flavored-cigar standards date from May 2022 and had not been listed as final rules as of early 2025. The Biden-era proposal was withdrawn by the incoming administration in January 2025, removing (for now) a major threat to Newport and menthol volumes.[29][30]
• Nicotine reduction — proposed, uncertain. In January 2025 the FDA advanced a proposal to cap nicotine in cigarettes at minimally addictive levels; its fate under the current administration is unclear.[29][30] This is the biggest open regulatory question for combustibles.
• Excise taxes. Federal $1.01/pack plus state taxes averaging ~$1.96/pack (range $0.17 Missouri to $5.35 New York).[11][18]
• Master Settlement Agreement (MSA). Under the 1998 accord, major manufacturers pay the states in perpetuity — roughly $200+ billion over the first 25 years, with continuing annual payments tied to cigarette volumes.[19] It functions as an ongoing per-pack cost.
• Minimum age. Federal "Tobacco 21" sets the legal purchase age at 21.
• Enforcement gap on illicit vapes. The FDA has authorized only a small number of tobacco-flavored e-cigarettes, yet thousands of unauthorized flavored disposables (mostly from China) are sold — an enforcement shortfall documented by government watchdogs.[26]

8. Competitive dynamics and consolidation

This is a textbook concentrated market. Federal data put the top-4 share of receipts at 90.6%.[3] In cigarettes specifically it behaves like a duopoly-plus: Altria's Marlboro is the dominant premium brand — Altria reported 45.2% of measured U.S. cigarette retail volume in 2025, including 40.5% for Marlboro alone — with Reynolds American/BAT (Newport, Camel) the clear #2, Imperial/ITG (Winston, Kool) #3, and Liggett/Japan Tobacco a distant #4.[5][7][9]

Decades of consolidation produced today's structure:

• BAT acquired Reynolds American outright in 2017 (~$49 billion), after Reynolds had absorbed Lorillard/Newport.[7]
• PMI acquired Swedish Match (Zyn) in 2022, pivoting toward smoke-free.[6]
• Japan Tobacco bought Vector Group/Liggett in 2024, completing the ~$2.4 billion deal on October 7, 2024 and taking the #4 U.S. player private.[8]

The competitive battleground has shifted from cigarette share to nicotine pouches and heated tobacco, where Zyn's early dominance, capacity investments and the new FDA reduced-risk claim give PMI an edge that Altria (on!) and BAT (Velo) are spending to close.[20][21][28]

9. Risks

• Structural volume decline. Cigarette volumes fall ~8–10% a year; if pricing power ever fails to offset that, the cash-cow model breaks.[5][16]
• Regulation. A revived nicotine-reduction cap, new flavor bans, or steep excise increases could sharply cut volumes or profitability. A nicotine cap could alter the value of existing formulations and brands, accelerate switching, or encourage illicit supply.[29][30]
• Illicit competition. Unauthorized Chinese disposable vapes — estimated at $2.4+ billion of U.S. sales in 2024 and ~35% of convenience-store e-cigarette sales — undercut both legal vapes and, indirectly, cigarettes and pouches.[26]
• Litigation and MSA drag. Ongoing settlement payments and product-liability exposure remain permanent costs.[19]
• Smoke-free execution risk. New categories can disappoint: Altria took a ~$2.2 billion impairment on NJOY after a patent ruling forced products off shelves.[12]
• Down-trading. In weak economies, smokers shift to discount brands, pressuring premium mix. Discount reached 31.8% of retail volume in 2025.[5]
• ESG exclusion. Many institutional funds cannot own tobacco, structurally capping the buyer base and valuation multiples.
• Leaf supply. Raw leaf is exposed to weather, disease, acreage decisions, curing-energy prices, and farm labor. Global sourcing and aged inventories soften any single U.S. harvest shock, but production concentration in few facilities makes plant closures or strikes material.

10. How to invest and the outlook

Public-market routes.

• Income / U.S. pure play: Altria (MO) — high yield, Dividend-King track record, but tied to the fastest-declining (U.S. cigarette) market and dependent on smoke-free execution.[5][12]
• Smoke-free growth: Philip Morris International (PM) — Zyn plus IQOS give it the industry's clearest growth story, at a higher valuation.[6][21]
• Value / yield with U.S. exposure via a parent: British American Tobacco (BTI ADR) owns Reynolds American.[7]
• Smaller U.S. cigarette position: Imperial Brands (IMB, LSE) owns ITG Brands with Winston, Kool, and mass-market cigars.[9]
• Niche small-cap: Turning Point Brands (TPB) — Zig-Zag and Stoker's.[13]
• Supply chain: Universal Corporation (UVV) — leaf processing, a more commodity-like, income-oriented profile.[14]
• Speculative: 22nd Century Group (XXII) — reduced-nicotine cigarettes; distressed and high-risk.[15]
• Funds: no dominant U.S.-tobacco ETF; broad consumer-staples funds hold MO/PM, while ESG funds exclude the sector.

Private / other routes. Because the branded core is already consolidated inside public multinationals or foreign parents, private opportunities cluster at the edges: leaf growing and processing, cigar manufacturing, contract manufacturing, distribution and convenience retail, and independent nicotine-pouch or vape startups (which sit in adjacent NAICS codes and face the PMTA gauntlet). Diligence must establish whether the target's products possess valid FDA marketing status, whether it is an MSA participating or nonparticipating manufacturer, what escrow obligations apply, who owns product applications and formulas, and whether claimed "market size" includes vaping or tobacco-free nicotine that falls outside NAICS 312230.

Near-term drivers to watch (forward-looking).

• Whether pricing power continues to offset ~8–10% annual cigarette volume declines.[5][16]
• The trajectory of nicotine pouches — can on! and Velo dent Zyn's ~74% share, and how fast does the ~30%+ market growth hold.[20][21]
• The fate of the FDA nicotine-reduction proposal and any return of flavor restrictions.[29][30]
• Enforcement (or not) against illicit disposable vapes, which shapes the legal smoke-free opportunity.[26]

The reasoned base case is that combustible cigarettes keep shrinking while manufacturers defend cash flows through price, and the winners over the next decade are whoever best converts that declining combustible profit pool into leadership in pouches and other reduced-risk nicotine products. It is a high-cash, high-yield sector for income investors who can accept secular decline, regulatory overhang and ESG exclusion — with the smoke-free transition as the swing factor.

---

Sources

1. U.S. Census Bureau / NAICS Association. "NAICS Code 312230 — Tobacco Manufacturing (2022 definition and exclusions)." 2022. https://www.census.gov/naics/?details=312230&input=312230&year=2022
2. U.S. Census Bureau. "County Business Patterns, NAICS 312230." 2023. (Establishments, employment, payroll — Histometrics ingested federal data.) https://www.census.gov/programs-surveys/cbp.html
3. U.S. Census Bureau. "Economic Census — Concentration Ratios and Receipts, NAICS 312230." 2022. (Firms, receipts, CR4/CR8/CR20/CR50; HHI suppressed.) https://www.census.gov/programs-surveys/economic-census.html
4. Bureau of Labor Statistics. "Industry Productivity: Sectoral Output, NAICS 312230." 2025. https://fred.stlouisfed.org/series/IPUEN312230T300000000
5. Altria Group, Inc. "Altria Reports 2025 Fourth-Quarter and Full-Year Results." 2026. https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2025-Fourth-Quarter-and-Full-Year-Results-Provides-2026-Earnings-Guidance/default.aspx
6. Philip Morris International Inc. "Philip Morris International Reports 2024 Fourth-Quarter & Full-Year Results." 2025. https://www.pmi.com/investor-relations/press-releases-and-events/press-releases-overview/press-release-details?newsId=28366
7. Wikipedia / Reynolds American Inc. "Reynolds American." 2024. https://en.wikipedia.org/wiki/Reynolds_American
8. Japan Tobacco / SEC. "Completion of Vector Group Acquisition." October 2024. https://www.sec.gov/Archives/edgar/data/59440/000110465924106503/tm2425692d1_ex99-a5f.htm
9. Imperial Brands plc. "U.S. Operations." 2025. https://www.imperialbrandsplc.com/careers/our-locations
10. U.S. Small Business Administration. "Table of Size Standards, NAICS 312230 (1,500 employees)." 2023. https://www.sba.gov/document/support-table-size-standards
11. Centers for Disease Control and Prevention. "STATE System Excise Tax Fact Sheet" (federal $1.01/pack; average state $1.96/pack). 2024. https://www.cdc.gov/statesystem/factsheets/excisetax/ExciseTax.html
12. Sure Dividend. "Dividend Kings In Focus: Altria Group" (dividend streak, yield, NJOY impairment). 2025. https://www.suredividend.com/dividend-kings-mo/
13. Turning Point Brands, Inc. "Turning Point Brands Announces Fourth Quarter and Full Year 2024 Results." 2025. https://www.businesswire.com/news/home/20250306952780/en/Turning-Point-Brands-Announces-Fourth-Quarter-and-Full-Year-2024-Results
14. Universal Corporation. "Universal Corporation Reports Annual Results (FY2024, ~$2.7B revenue)." 2024. https://www.prnewswire.com/news-releases/universal-corporation-reports-annual-results-302153294.html
15. StockTitan. "22nd Century Group Reports Fourth Quarter and Full-Year Results" (VLN losses, reverse split). 2025. https://www.stocktitan.net/news/XXII/
16. Tobacco Monitoring / CDC Foundation. "Changes in U.S. and State Cigarette Sales — Annual Data Brief" (6.9B packs in 2024, -9.2%; -8.2% in 2025). 2025. https://tobaccomonitoring.org/wp-content/uploads/2025/03/Annual-Cigarette-Data-Brief-for-Total-US-and-Selected-States-2024.pdf
17. Federal Trade Commission. "Cigarette Report for 2022" (173.5B cigarettes, 36% menthol, promotional spending). 2023. https://www.ftc.gov/system/files/ftc_gov/pdf/2022-Cigarette-Report.pdf
18. Alcohol and Tobacco Tax and Trade Bureau. "Tax Rates — Tobacco Products." 2025. https://www.ttb.gov/taxes/tax-audit/taxes-and-filing/tax-rates
19. Public Health Law Center. "Master Settlement Agreement" (~$200B+ payments, perpetual annual payments). 2024. https://www.publichealthlawcenter.org/topics/commercial-tobacco-control/master-settlement-agreement
20. GlobeNewswire / Research and Markets. "United States Nicotine Pouches Market Forecast Report 2025-2033" (~$4B in 2024, ~30%+ CAGR). 2025. https://www.globenewswire.com/news-release/2025/04/21/3064762/0/en/United-States-Nicotine-Pouches-Market-Forecast-Report-2025-2033.html
21. Philip Morris International Inc. "PMI 2025 Annual Report" (930.2M cans Americas oral, 797.9M nicotine-pouch cans). 2026. https://www.sec.gov/Archives/edgar/data/0001413329/000162828026021174/pmi_2025xannualreport.pdf
22. Tobacco Insider. "USA: ZYN Pouches" (~74% share). 2025. https://tobaccoinsider.com/zyn-pouches/
23. U.S. Department of Agriculture. "Crop Production 2025 Summary" (359M lbs, 171,300 acres, 2,093 lbs/acre). 2026. https://www.nass.usda.gov/Publications/Todays_Reports/reports/cropan26.pdf
24. U.S. Department of Agriculture. "Crop Values 2025 Summary" ($831.5M value, $2.319/lb). 2026. https://www.nass.usda.gov/Publications/Todays_Reports/reports/cpvl0226.pdf
25. Centers for Disease Control and Prevention / NCHS. "FastStats — Smoking" (9.1% adult smoking, 6.7% e-cigarette use in 2025). 2026. https://www.cdc.gov/nchs/fastats/smoking.htm
26. Reuters via AOL / U.S. GAO. "Illegal U.S. vape sales worth at least $2.4 billion in 2024." 2025. https://www.aol.com/news/illegal-u-vape-sales-worth-103028304.html
27. Tobacco Insider / FDA. "The US FDA: PMTA" (premarket review timelines). 2025. https://tobaccoinsider.com/the-us-fda-pmta/
28. U.S. Food and Drug Administration. "FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products." January 2025. https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-20-zyn-nicotine-pouch-products-after-extensive-scientific-review
29. Network for Public Health Law. "Three Federal Tobacco Regulatory Measures Up for Change in 2025" (menthol ban withdrawal; nicotine-reduction proposal). 2025. https://www.networkforphl.org/news-insights/three-federal-tobacco-regulatory-measures-up-for-change-in-2025/
30. U.S. Food and Drug Administration. "Tobacco Product Standards." 2025. https://www.fda.gov/tobacco-products/products-guidance-regulations/tobacco-product-standards